pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 48 | Non-oncology: 32 Oncology: 16 |
| Under Consideration for Negotiation | 20 | Non-oncology: 13 Oncology: 7 |
| Completed Negotiations | 741 | With Letter of Intent: 638 Without agreement: 103 |
| Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Venclexta | AbbVie Corporation | for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion (in combination with Imbruvica) | |
| Kymriah | Novartis Pharmaceuticals Canada Inc. | Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy | |
| Tagrisso | AstraZeneca Canada Inc. | In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 dele | |
| Osenvelt | Celltrion Healthcare Canada Ltd. | Multiple Indications | |
| Stoboclo | Celltrion Healthcare Canada Ltd. | Multiple Indications | |
| Fulphila | BGP Pharma ULC | Febrile neutropenia in non-myeloid malignancies | |
| Pexegra | Jamp Pharma Corporation | Febrile neutropenia in non-myeloid malignancies | |
| Axberi/Axberi HP | Baxter Corporation | Thrombosis and cardiovascular conditions (prevention or treatment) | |
| Ixifi | Pfizer Canada ULC | Multiple Indications | |
| Velsipity | Pfizer Canada ULC | Ulcerative Colitis | |
| Truqap | AstraZeneca Canada Inc. | Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative) |